@article {8253,
	title = {Intravesical interferon alfa-2b administration in the treatment of superficial bladder tumors},
	journal = {European Urology},
	volume = {18},
	year = {1990},
	note = {Cited By :14Export Date: 21 February 2017},
	month = {1990},
	pages = {201 - 203},
	abstract = {This study was undertaken to assess the value of intravesical interferon alfa-2b treatment in preventing the recurrences of superficial transitional cell carcinoma of the bladder. A total of 30 patients aged from 33 to 78 entered the protocol. The intravesical instillations were performed once a week for 8 weeks. A solution of 10 x 106 IU interferon alfa-2b in 30 ml of normal saline was used. Follow-up ranged from 12 to 28 months. Of the 30 patients, 19 (63.33\%) were tumor free at the end of follow-up. Of the remaining 11 patients, 7 presented with recurrent superficial tumors and 4 with invasive bladder tumors. No side effects were noted.},
	keywords = {interferon alfa-2B, Superficial bladder tumors},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025002154\&partnerID=40\&md5=dab72fee418505785a3ef6fba74fb266},
	author = {Kostakopoulos, A. and Deliveliotis, C. and Mavromanolakis, E. and Aravantinos, G. and Dimopoulos, M.A.}
}
